The cancer immunotherapy pipeline, displays a high level of first-in-class innovation with novel developments focusing heavily on producing the next big immune checkpoint inhibitor, according to GBI Research. GBI Research’s
Tag "GBI Research"
Roche’a anticipated approval of ocrelizumab will drive the company’s share of the market from <1% in 2016 to 15% by 2022, according to GBI Research The company’s report states that
Advertisements
